Topline
Eli Lilly on Monday lowered the cost of Zepbound after the pharmaceutical giant and Ozempic maker Novo Nordisk announced a deal with the Trump administration to slash the prices of the popular weight-loss drugs.
The pharmaceutical giant and Novo Nordisk said they would lower the prices of their popular weight loss drugs to expand access.
Copyright 2017 The Associated Press. All rights reserved.
Key Facts
The out-of-pocket monthly price for the lowest single-dose vial of Zepbound is now $299 when purchased through Eli Lilly’s platform LillyDirect, a 14% decrease from $349, while the 5-milligram dose was cut to $399, a roughly 20% cut from $499, Eli Lilly announced.
Prices for the 7.5 through 15 milligram doses were reduced to $449 from $499.
Novo Nordisk announced last month the out-of-pocket monthly price of Ozempic and Wegovy would be lowered to $349 from $499, and that the two lowest doses of either drug would be available for $199 per month for the first two months.
Eli Lilly’s shares fell nearly 1% in premarket trading after the announcement, while Novo Nordisk’s stock traded down more than 1.7%.
Big Number
$1,086. That’s the monthly cost of Zepbound before any discounts or rebates, according to Eli Lilly. The list price for Ozempic is just over $997 per month.